Adjuvant Atezolizumab Sustains Survival vs BSC in Stage IB to IIIA NSCLC

被引：0
|
作者：
Vose, Julie M. [1 ]
机构：
[1] Univ Nebraska Med Ctr, Buffett Canc Ctr, Div Hematol Oncol, Omaha, NE 68198 USA
来源：
ONCOLOGY-NEW YORK | 2024年 / 38卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：44
相关论文
共 50 条
  • [21] Adjuvant atezolizumab in Japanese patients with resected stage IB-IIIA non-small cell lung cancer (IMpower010)
    Kenmotsu, Hirotsugu
    Sugawara, Shunichi
    Watanabe, Yasutaka
    Saito, Haruhiro
    Okada, Morihito
    Chen-Yoshikawa, Toyofumi Fengshi
    Ohe, Yuichiro
    Nishio, Wataru
    Nakagawa, Shizuka
    Nagao, Haruka
    CANCER SCIENCE, 2022, 113 (12) : 4327 - 4338
  • [22] Refining the role of adjuvant chemotherapy in stage IB and IIA NSCLC.
    Pathak, Ranjan
    Hoag, Jessica R.
    Goldberg, Sarah B.
    Monsalve, Andres F.
    Resio, Benjamin
    Boffa, Daniel J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [23] Impact on Survival on Interval between Surgery and Adjuvant Chemotherapy in Completely Resected Stage IB-IIIA Lung Cancer
    Wang, Bing-Yen
    Huang, Jing-Yang
    Hung, Wei-Heng
    Lin, Ching-Hsiung
    Lin, Sheng-Hao
    Liaw, Yung-Po
    Ko, Jiunn-Liang
    PLOS ONE, 2016, 11 (11):
  • [24] Multi-centre randomized controlled study comparing adjuvant vs neo-adjuvant chemotherapy with docetaxel plus carboplatin in resectable stage IB to IIIA NSCLC: final results of CSLC0501
    Wu, Y-L.
    Yang, X-N.
    Zhong, W.
    Ben, X.
    Qiao, G-B.
    Wang, Q.
    Wang, C.
    Luo, H-H.
    Wang, Z.
    Yan, H-H.
    ANNALS OF ONCOLOGY, 2016, 27
  • [25] IMpower010: Final disease-free survival (DFS) and second overall survival (OS) interim results after ≥5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA non-small cell lung cancer (NSCLC).
    Wakelee, Heather A.
    Altorki, Nasser K.
    Zhou, Caicun
    Csoszi, Tibor
    Vynnychenko, Ihor O.
    Goloborodko, Oleksandr
    Rittmeyer, Achim
    Reck, Martin
    Martinez-Marti, Alex
    Kenmotsu, Hirotsugu
    Chen, Yuh-Min
    Chella, Antonio
    Sugawara, Shunichi
    Fu, Chenqi
    Ballinger, Marcus
    Deng, Yu
    Srivastava, Minu K.
    Bennett, Elizabeth
    Gitlitz, Barbara Jenifer
    Felip, Enriqueta
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA8035 - LBA8035
  • [26] NSCLC Stage IIIA: Delayed Surgery after Induction shortens Survival
    Dobler, Gabriele
    ZENTRALBLATT FUR CHIRURGIE, 2017, 142 (03): : 249 - +
  • [27] Adjuvant chemotherapy in stage IB NSCLC: Implication of the new TNM staging system
    Dediu M.
    memo - Magazine of European Medical Oncology, 2011, 4 (1) : 16 - 18
  • [28] Endostar in combination with postoperative adjuvant chemotherapy prolongs the disease free survival of stage IIIA NSCLC patients with high VEGF expression
    Chen, Zhiwei
    Luo, Qingquan
    Zhou, Zhen
    Jian, Hong
    Lu, Shun
    Liao, Meilin
    ONCOTARGET, 2017, 8 (45) : 79703 - 79711
  • [29] Osimertinib as adjuvant therapy in patients (pts) with stage IB-IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA
    Grohe, C.
    Herbst, R. S.
    Tsuboi, M.
    John, T.
    Majem, M.
    Goldman, J. W.
    Kim, S. -W.
    Marmol, D.
    Rukazenkov, Y.
    Wu, Y. -L.
    Engel-Riedel, W.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 138 - 138
  • [30] Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup Analysis
    Wang, Jie
    Wu, Yi-Long
    Lu, Shun
    Wang, Qun
    Li, Shanqing
    Zhong, Wen-Zhao
    Wang, Qiming
    Li, Wei
    Wang, Buhai
    Chen, Jun
    Cheng, Ying
    Duan, Hongbing
    Li, Gaofeng
    Shan, Li
    Liu, Yangbo
    Liu, Jing
    Huang, Xiangning
    Bolanos, Ana
    He, Jie
    JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (02):
12345